MyMD-1 is under clinical development by TNF Pharmaceuticals and currently in Phase I for Hashimoto Thyroiditis. According to GlobalData, Phase I drugs for Hashimoto Thyroiditis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MyMD-1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MyMD-1 overview
MyMD-1 (Isomyosamine) is under development for the treatment of multiple sclerosis, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, immune mediated, sarcopenia, frailty, chronic inflammation, rheumatoid arthritis, type 2 diabetes, inflammatory bowel disease, delay aging, cytokine storm and traumatic optic neuropathy (TON). It is a synthetic derivative of tobacco alkaloids, that is administered through oral route as capsule and tablet.
It was also under development for the treatment of depression.
TNF Pharmaceuticals overview
TNF Pharmaceuticals, formerly MyMD Pharmaceuticals Inc, is a clinical stage biopharmaceutical company that develops novel therapies for autoimmune and inflammatory conditions. The company’s pipeline products include MYMD-1 and Supera-CBD. MYMD-1 is for the treatment of Sarcopenia (Aging), Rheumatoid Arthritis, Immune Regulator, Hashimoto’s Thyroiditis, Additional Programs. Supera-CBD is for the treatment of Epilepsy, Chronic Pain and Anxiety. It uses pre-clinical and clinical longevity research for the development of drug products that target aging and age-related diseases, and alleviate chronic pain, anxiety, and sleep disorders. TNF Pharmaceuticals is headquartered in Baltimore, Maryland, in the US.
For a complete picture of MyMD-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
